A Phase 3 trial showed gotistobart significantly improved overall survival, with a 43% reduced risk of death, compared to docetaxel. Higher exposure to gotistobart was associated with improved survival, supporting the selected dosing regimen.
The PAPILLON trial demonstrates durable clinical benefit and longest median overall survival reported to date for people with lung cancer carrying an EGFR exon 20 insertion mutation. Amivantamab plus chemotherapy extended overall survival by a clinically meaningful 6 months and cut disease progression risk by 60%.
A randomized trial found that brain MRI surveillance alone preserves cognitive function without a difference in survival, supporting MRI surveillance as the standard of care for patients with small cell lung cancer. No apparent difference was observed in overall survival and progression-free survival between the groups.
The PAPILLON study demonstrates the longest overall survival for patients with EGFR exon 20 insertion-positive advanced NSCLC using first-line amivantamab-chemotherapy. The study found a median overall survival of 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy.
The eight-year ADAURA update reports a significant overall survival benefit with adjuvant osimertinib in patients with completely resected, EGFR-mutated stage IB-IIIA NSCLC. The study found an eight-year overall survival rate of 74% with osimertinib versus 58% with placebo.
The Phase 3 DESTINY-Lung04 trial showed that trastuzumab deruxtecan significantly improves progression-free survival in patients with HER2-mutant non-small cell lung cancer, with a median PFS of 14.3 months compared to 8.3 months with pembrolizumab plus chemotherapy. T-DXd also demonstrated a higher objective response rate and better d...
The phase III TAISHAN-302 trial found Tam-Peli to significantly improve overall survival, progression-free survival, and objective response rate in patients with relapsed small-cell lung cancer compared to topotecan. The study also showed a favorable safety profile for Tam-Peli.
The Phase 3 IMpower030 trial found that perioperative atezolizumab plus chemotherapy doubled event-free survival to 62.8 months compared to 34.9 months for chemotherapy alone. The study also showed higher pathological response rates with the atezolizumab regimen.
The Phase III ARTEMIS-008 trial shows that risvutatug rezetecan significantly improves overall survival in patients with relapsed small-cell lung cancer. The treatment reduced the risk of death by 54% and improved progression-free survival and response rates compared to topotecan.
A phase 3 trial shows ivonescimab significantly improves overall survival compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. The median overall survival was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab.
A new study found that community first responders did not improve short-term survival after cardiac arrest, but did increase bystander CPR and defibrillation rates. The study's findings suggest that the effect of first responders on survival is highly dependent on the time available for intervention.
A new study by UCLA ornithologists found that female birds have a 12.4% lower adult survival rate than males in 35 species. Females lived an average of 1.36 years after reaching adulthood, while males lived 1.61 years.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.
The NRG Oncology trial showed a sustained overall survival benefit for patients with advanced or recurrent endometrial cancer treated with pembrolizumab and chemotherapy, even after post-study immunotherapy. The benefit persisted in both mismatch repair proficient and deficient populations.
A study of 152 patients with recurrent HCC compared the efficacy of sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) versus SBRT alone. The combination showed a favorable trend toward improved survival without increased severe toxicity.
A nighttime response during out-of-hospital cardiac arrest is associated with lower odds of sustained return of spontaneous circulation, neurologically favorable survival, and postresuscitation survival. Emergency care factors only account for a portion of the decreased survival rates at night.
A new method called scSurvival uses single-cell genetic data to identify which cells inside a tumor are most strongly linked to patient survival. The approach pinpoints harmful and helpful cell populations that can drive disease progression, enabling better understanding of why patients with the same cancer have different outcomes.
A global, multicentre phase III trial demonstrates the potential of Dato-DXd as an effective new treatment option for triple-negative breast cancer. The novel antibody-drug conjugate (ADC) nearly doubles overall survival and improves progression-free survival in patients with untreated, advanced TNBC.
The study found that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies, highlighting the need for careful patient selection and monitoring.
A study of over 2,300 North Carolina women with ovarian cancer found that both quick and delayed diagnoses had worse survival rates than those diagnosed in the middle. Considering patient severity may improve outcomes for some symptomatic patients.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
A new study found that commonly prescribed cardiovascular medications, such as statins and diuretics, do not worsen survival in multiple myeloma patients. The research suggests that these medications can often be continued without clear evidence of harming survival outcomes.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
Women with stage IV breast cancer detected through screening have a 60% chance of survival ten years after diagnosis, compared to under 20% without screening. Screening may not be too late to treat successfully, even at the most serious stage of the disease.
A major study has shown that tumour stage at diagnosis is strongly linked to childhood cancer survival across six different cancers. Researchers analysed data from 9,883 children in 27 countries and found significant variation in three-year survival rates between regions, particularly in the UK and Ireland.
Research finds that reducing wolves improves caribou calf survival in mountainous regions due to the inability of bears and wolverines to catch older calves. In contrast, flatter landscapes with accessible trails see no improvement in survival rates as other predators fill the gap.
A study analyzing 3225 trauma patients in South East England found that air ambulance pre-hospital care significantly improved survival rates, with 2125 patients exceeding 30-day survival. Those most likely to benefit were severely injured patients with moderate probability of survival, who unexpectedly survived for 30 days.
A new study of over 32,000 US Veterans found that longer treatment with medications for opioid use disorder is associated with a greater probability of short- and medium-term survival. The benefit continues to increase at least for four years of ongoing treatment.
A major international study reveals significant disparities in childhood cancer survival rates worldwide. The global average is just 37% survival rate, while high-income countries boast an 80% rate. Better monitoring and investment in healthcare are critical to achieve the WHO's goal of at least 60% survival by 2030.
A new study identifies a practical and powerful prognostic marker that can help clinicians tailor treatment strategies to improve survival for patients with aggressive T-cell lymphoma. Researchers found that patients who relapse within 12 months of initial therapy have a dramatically declining chance of survival, making targeted therap...
A study of over 60,000 US patients with advanced breast cancer found average survival times increased by six to seven months since 2011. Researchers attribute the improvement to more effective treatments, wider diagnosis, and quality of care advancements.
A study of 12,490 dementia cases found significant variations in survival times among early onset dementia patients by clinical subtype. The study revealed that those with frontotemporal dementia or Lewy body dementia had the shortest survival time, while Alzheimer's disease and vascular cognitive impairment had longer average survival...
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
The proton therapy cohort of NRG-BN001 demonstrated improved overall survival (OS) for patients with newly diagnosed glioblastoma, with a 6.8% absolute survival advantage at 2 years. The results support the development of a phase III randomized trial to confirm these findings.
The FLAURA2 trial shows osimertinib plus chemotherapy significantly improves overall survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC. The combination also demonstrates a manageable safety profile, extending survival for these patients.
A retrospective cohort study found that adjuvant chemotherapy improves survival in resected early-onset pancreatic cancer patients after neoadjuvant therapy. EOPC patients showed superior survival compared to average-onset pancreatic cancer, with ACT further enhancing outcomes.
A long-term study in southeastern Madagascar found that protected forest fragments improve the survival of endangered mouse lemurs. The study suggests that habitat protection is critical for conserving this species.
A European study analyzed data from over 30,000 children with brain tumors, providing a clear overview of their survival outcomes. The study found that differences in survival rates between countries are smaller than previously thought, suggesting improved access to similar treatments across Europe.
A new study found that surgical ablation during coronary artery bypass grafting (CABG) is associated with a risk-adjusted median survival advantage of 4.4 months compared to those who did not receive ablation. Patients treated by surgeons who frequently performed the procedure had an even greater median survival advantage.
A major international study found that deceased-donor kidney transplantation offers a consistent survival advantage with standard-criteria kidneys, but the benefit plateaus in older and high-risk recipients. The study used a robust target trial emulation framework to compare long-term survival between transplant patients and those on d...
Scientists developed an AI method using ensemble techniques to predict overall survival rate of prostate cancer patients. Gradient Boosting performed exceptionally well, achieving a perfect score in accuracy and precision.
A Dana-Farber study found that patients with stage III colon cancer who consumed an anti-inflammatory diet had longer overall survival post-treatment compared to those on a proinflammatory diet. Engaging in higher levels of physical activity also amplified the positive influence on survival.
A Phase III trial led by MD Anderson Cancer Center demonstrates a triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improves progression-free survival and overall survival in BRAF V600E-mutated metastatic colorectal cancer. The regimen offers a clear survival advantage over standard chemotherapy alone.
A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...
Researchers used AI-driven methods to analyze thousands of digital images of melanoma tumor tissue, identifying key immune cell structures that boost immunotherapy effects. The presence of these structures was linked to significantly better overall survival for patients with advanced melanoma.
A new study found that survival rates for athletes suffering sudden cardiac arrest vary significantly by race, with 57% of Black athletes and 54% of other race athletes dying between 2014-2023. Improved emergency preparedness likely played a role in increased survival rates.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
Increased visceral adipose tissue density and decreased skeletal muscle area are predictors of post-esophagectomy pulmonary complications. Decreased skeletal muscle density is associated with poorer overall survival. Routine morphomic analysis can help identify patients at risk and tailor perioperative care.
A new study published in the European Journal of Cardio-Thoracic Surgery found that mechanical heart valve replacements have better long-term survival rates compared to biological valves. Patients who received mechanical valves had improved survival up to 13 years after surgery, with smaller valves showing greater benefits.
Research presented at the 2025 STS Annual Meeting reveals that anatomic lung resections such as lobectomy and segmentectomy are associated with improved long-term survival compared to wedge resection for stage 1A NSCLC. Lobectomy offered the highest survival rates, with a 71.9% 5-year OS and 44.8% 10-year OS.
A phase III trial found that combining radiotherapy with cetuximab improved disease-free survival in patients with HPV-negative head and neck cancer, but not overall survival. The treatment was also associated with higher rates of acute toxicity.
A study analyzing over a million Medicare patients found that those receiving multi-arterial grafts had improved survival compared to single-arterial graft recipients. However, when accounting for unmeasured confounding variables using surgeon preference as an instrumental variable, no difference in long-term survival was observed.
A recent study found that cancer patients who traveled to local or national healthcare centers had higher five-year survival rates compared to those who remained in their residential cities. The study highlights critical disparities in healthcare resource allocation and quality across regions.
A randomized phase 2 clinical trial shows that adding high-dose, intravenous vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. Patients also experience improved quality of life with reduced side effects.
A new study from Japan confirms that definitive criteria for lower cachexia prevalence rates are linked to reduced survival rates in cancer patients. The study found that the diagnostic criteria used for cachexia detection can affect reported prevalence and survival outcomes, emphasizing the need for accurate diagnosis.
The German wolf population boasts the world's highest survival rates of wolves, with young wolves reaching 75% annual survival probability. The expansion is attributed to suitable habitats and protection, leading to a median survival time of three years.
A clinical trial shows promise in using a gene signature to tailor chemotherapy for high-risk breast cancer patients, improving disease-free survival rates. Patients classified as low risk had significantly higher rates of disease-free and overall survival compared to those at high risk.
Researchers found that multi-source data linkage enhances reliability of population-based cancer survival estimates in a metropolitan Chinese cancer registry. The study's findings have significant public health implications for optimizing cancer patient follow-up strategies in China and other developing countries.
A recent analysis reveals that the Dependent Coverage Expansion (DCE) provision of the Affordable Care Act has improved the survival rates and reduced the death rates of young adults diagnosed with cancer. The study found a significant improvement in both cancer survival and death rate trends after ACA implementation, particularly for ...
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.